Vertex Pharmaceuticals’ Alyftrek Receives the CHMP’s Positive Opinion for the Treatment of Cystic Fibrosis
Shots:
- The CHMP has recommended Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) to treat patients (≥6yrs.) with cystic fibrosis (CF), having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Alyftrek is approved in the US and UK and is under review in Canada, Switzerland, Australia, and New Zealand
- Vanzacaftor & tezacaftor help increase CFTR protein at the cell surface, while deutivacaftor enhances its function by boosting channel open probability to improve salt and water flow
- In trials, Alyftrek matched Kaftrio (ivacaftor/tezacaftor/elexacaftor) on ppFEV1 and outperformed it in reducing sweat chloride
Ref: Vertex | Image: Vertex
Related News:- Vertex Receives the US FDA Approval for Journavx (Suzetrigine) to Treat Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
